Evidence map›Paper›PMID 34884663›Full record

ArticleInternational journal of molecular sciences2021

GM1 Is Cytoprotective in GPR37-Expressing Cells and Downregulates Signaling.

Ellen Hertz, Marcus Saarinen, Per Svenningsson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Lipids in Neurodegenerative Diseases.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ellen HertzDepartment of Clinical Neuroscience, Karolinska Institutet, Biomedicum, J5:20, Karolinska University Hospital, Solna, 171 64 Stockholm, Sweden.
Marcus SaarinenDepartment of Clinical Neuroscience, Karolinska Institutet, Biomedicum, J5:20, Karolinska University Hospital, Solna, 171 64 Stockholm, Sweden.
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institutet, Biomedicum, J5:20, Karolinska University Hospital, Solna, 171 64 Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

European Research Council 649116
6 · The paper itself

Abstract

G-protein-coupled receptors (GPCRs) are commonly pharmacologically modulated due to their ability to translate extracellular events to intracellular changes. Previously, studies have mostly focused on protein-protein interactions, but the focus has now expanded also to protein-lipid connections. GM1, a brain-expressed ganglioside known for neuroprotective effects, and GPR37, an orphan GPCR often reported as a potential drug target for diseases in the central nervous system, have been shown to form a complex. In this study, we looked into the functional effects. Endogenous GM1 was downregulated when stably overexpressing GPR37 in N2a cells (N2a

Indexed as

AnimalsCytoprotectionDown-RegulationGene Expression Regulation, NeoplasticG(M1) GangliosideHEK293 CellsHumansMiceNeuroblastomaNeuroprotective AgentsReceptors, G-Protein-CoupledSignal TransductionG(M1) GangliosideGpr37 protein, mouseGPR37 receptor, humanNeuroprotective AgentsReceptors, G-Protein-CoupledcytoprotectionGM1GPCRGPR37orphan receptorParkinson’s disease

Identifiers

PMID34884663
PMCPMC8657933
OpenAlexW3216287732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.